Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleRheumatoid Arthritis
Open Access

Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry

Leslie R. Harrold, Jenny Griffith, Patrick Zueger, Heather J. Litman, Bernice Gershenson, Syed S. Islam, Christine J. Barr, Dianlin Guo, Jonathan Fay and Jeffrey D. Greenberg
The Journal of Rheumatology July 2020, 47 (7) 959-967; DOI: https://doi.org/10.3899/jrheum.190260
Leslie R. Harrold
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lharrold@corrona.org
Jenny Griffith
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Zueger
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather J. Litman
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernice Gershenson
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syed S. Islam
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine J. Barr
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dianlin Guo
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Fay
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. Greenberg
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Waltham, Massachusetts; AbbVie, North Chicago, Illinois; New York University School of Medicine, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To assess longterm safety in a US cohort of patients with rheumatoid arthritis (RA) treated with adalimumab (ADA) in real-world clinical care settings.

Methods. This observational study analyzed the longterm incidence of safety outcomes among patients with RA initiating ADA, using data from the Corrona RA registry. Patients were adults (≥ 18 yrs) who initiated ADA treatment between January 2008 and June 2017, and who had at least 1 followup visit.

Results. In total, 2798 ADA initiators were available for analysis, with a mean age of 54.5 years, 77% female, and mean disease duration of 8.3 years. Nearly half (48%) were biologic-naive, and 9% were using prednisone ≥ 10 mg at ADA initiation. The incidence rates per 100 person-years for serious infections, congestive heart failure requiring hospitalization, malignancy (excluding nonmelanoma skin cancer), and all-cause mortality were 1.86, 0.15, 0.64, and 0.33, respectively. The incidence of serious infections was higher in the first year of therapy (3.44, 95% CI 2.45–4.84) than in subsequent years, while other measured adverse effects did not vary substantially by duration of exposure. The median time to ADA discontinuation was 11 months, while the median time to first serious infection among those experiencing a serious infection event was 12 months.

Conclusion. Analysis of longterm data from this prospective real-world registry demonstrated a safety profile consistent with previous studies in patients with RA. This analysis did not identify any new safety signals associated with ADA treatment and provides guidance for physicians prescribing ADA for extended periods.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • DRUG SAFETY
  • ADALIMUMAB
  • ADVERSE EFFECTS
  • REGISTRIES

Rheumatoid arthritis (RA) is a complex immune-mediated inflammatory disease, which, if not treated effectively, can cause significant pain and progressive joint damage leading to disability and a reduced quality of life1,2. When compared with the general population, RA is associated with increased morbidity due to complications and comorbidities such as serious infections, cardiovascular (CV) disease, and certain cancers3,4,5. Higher mortality rates have also been reported3,5. Inhibition of tumor necrosis factor (TNF), a key component of the inflammatory mechanism associated with many immune-mediated diseases, has been shown to reduce RA disease activity and improve clinical, radiographic, and functional outcomes6,7.

TNF inhibitors (TNFi) have been associated with a reduced risk of CV disease in patients with RA8,9; however, some uncertainty remains on the increased risk of infections and the increased potential for malignancy and other adverse events (AE) in patients treated with TNFi. Prior studies have reported an increased risk of serious infections and malignancies, particularly lymphoma, in patients with psoriasis treated with TNFi, while other more recent studies have not identified similar significantly increased risks among patients treated with TNFi10–18. Because TNF is an important component of the human immune system and has a role in tumor growth mediation, the link between its inhibition and an increase in the frequency of serious infections or malignancies deserves more investigation19.

To date, more than 20 years after the introduction of TNFi, the safety of biologics such as adalimumab (ADA) has been established through both randomized controlled clinical trials (RCT) and registry-based European observational studies17,18,20,21,22. A large cross-indication (including RA, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and Crohn disease) analysis of longterm safety based on almost 30,000 patients treated with ADA in global clinical trials and open-label extension studies did not identify any new safety signals, although individual differences between the disease populations did exist17,18. Additionally, in these studies the mortality rate for most indications was below what would be expected in an age- and sex-adjusted population17,18. However, the patient populations from RCT and open-label extension studies may not be reflective of a real-world population of patients with RA in the United States. Comparisons between different registry-based studies are also challenging because of differences in design, followup assessments, and other variables assessed within each registry, which may result in heterogeneity between studies23. For example, the percentage of patients with a high Disease Activity Score has been shown to vary between registries, with patients in the Corrona registry having lower disease activity and higher functional status23,24. Differences in healthcare delivery systems and baseline patient characteristics between European and US populations may result in differences in the underlying risk of certain AE, highlighting the need to establish the safety profile of TNFi in both of these populations.

The longterm incidence of AE among ADA users in real-world clinical settings has not been well documented in the US. In a recent US study, about half of biologic-naive patients with RA stated that their unwillingness to initiate treatment with a biologic was primarily due to fear/concern about side effects, highlighting the need to clarify the safety of biologics such as ADA in US real-world practice25. The objective of our study was therefore to build on the existing knowledge base on the safety of TNFi through the evaluation of the risk of AE in relation to duration of ADA exposure in a US-based population. This will complement ongoing longterm clinical trial safety analyses and further test the hypothesis that the real-world safety profile of ADA is consistent with that previously demonstrated by RCT analyses as well as ex-US RA registries.

MATERIALS AND METHODS

Study design

This was a retrospective analysis of the US Corrona RA Registry, a prospective observational cohort of patients with RA initiated in 200126, which contains data on nearly 50,000 patients across 40 states, covering about 373,000 visits and 173,000 person-years (PY) of followup. Data are collected from both patients and their treating rheumatologists, who gather information on disease duration, prognosis, disease severity and activity, comorbidities, use of medications, and patient-reported outcome data. Participating rheumatologists also actively assess for the occurrence of AE at each registry followup visit. Followup assessments are requested as often as every 6 months and completed during routine clinical encounters.

Study population

Patients were included in this analysis if they were adults (≥ 18 yrs of age), initiated ADA as therapy for a clinical diagnosis of RA between January 1, 2008, and June 1, 2017, and were enrolled in the US Corrona RA Registry. Patients were also required to have at least 1 followup visit post-drug initiation. Patients with RA onset prior to 16 years of age were excluded from the study.

Ethics

All patients provided written informed consent prior to registry participation. Institutional review board (IRB) approvals for this study were obtained from a central IRB (New England Independent Review Board, NEIRB No. 02-021) for private practice sites and local IRB of participating academic sites.

Exposure

The date on which each patient initiated ADA therapy was defined as their index date and served as the starting point for the measurement of both the time to first AE and the incidence of the AE over time.

Outcomes and covariates

The safety outcomes assessed in this analysis were physician-reported serious infections (i.e., those requiring hospitalization or intravenous antibiotics), malignancies (excluding nonmelanoma skin cancer), congestive heart failure (CHF) that required hospitalization, tuberculosis (TB) with a focus on active TB, and drug-induced systemic lupus erythematosus. All-cause mortality was also assessed. Outcomes were assessed by both time from ADA initiation to the first occurrence of a specific AE, and the frequency, or incidence, of each specific AE over time. Measurement of these outcomes continued until either the first occurrence of the specific AE, or for incidence of the specific AE over time, until 90 days following discontinuation of ADA or the patient’s last Corrona visit (whichever occurred first), at which point the patient was censored. For malignancy and mortality, all events occurring during followup were included regardless of ADA continuation or discontinuation.

The Corrona registry uses an established system for the validation of physician-reported AE. In brief, treating physicians complete Targeted Adverse Event questionnaires to record serious AE. These questionnaires, alongside supporting documents appropriate to the event (e.g., hospitalization records, pathology reports), are submitted to Corrona for validation. A subset of questionnaires is also studied for expert adjudication. This methodology has been supported by previous validation studies, which found positive predictive values of Targeted Adverse Event forms to be 96% for CV events27, 86% for malignancies28, and 71% for serious infectious events29.

Analysis

Demographic and disease characteristics, including prior treatment history, of all patients at the time of their ADA therapy initiation were recorded. Percentages were used to describe categorical variables while means and SD were used to describe continuous variables. In cases of highly skewed distributions, medians and interquartile ranges were used to describe continuous variables.

The time from ADA initiation to the first occurrence of a specific AE was included in the analysis of incident events. For each specific AE, only patients without a history of that AE prior to or at the time of ADA initiation were followed for the occurrence of the AE.

Incidence rates (IR) and 95% CI are reported per 100 PY, assuming a Poisson distribution. Time to first event for particular events, including time to discontinuation, time to serious infection, and time to malignancy, was evaluated using Kaplan-Meier curves. Median (95% CI) time to first event was calculated as well as the proportion of patients who did not have an event at 6, 12, 24, 36, 48, 60, 72, and 84 months after ADA initiation. The standardized mortality ratio (SMR) was calculated based on recent Centers for Disease Control and Prevention mortality data30.

RESULTS

Study population at ADA initiation

In total, 2798 real-world patients who had initiated ADA therapy were available for analysis. Patient, disease, and prior treatment characteristics of these patients at time of ADA initiation are presented in Table 1. The mean (SD) age of these patients, who were predominantly female (77%), was 54.5 years (12.3 yrs), with a mean (SD) body mass index of 30.4 (7.5). About half of the patients (52%) had never smoked. The mean (SD) duration of disease was 8.3 (9) years, and the mean Clinical Disease Activity Index score was 20.4 (14), with 39% of the patients in the high disease activity category. About half (48%) were biologic-naive, and 9% were treated with ≥ 10 mg prednisone daily. The majority of patients (60%) were receiving concomitant methotrexate at ADA initiation. Additional patient, disease, and treatment characteristics are in Supplementary Table 1 (available with the online version of this article).

View this table:
  • View inline
  • View popup
Table 1.

Patient, disease, and prior treatment characteristics at ADA initiation.

Duration of ADA exposure during the assessment period

Overall, the majority of patients (84%) received ADA therapy for < 3 years (Table 1). The median time from ADA initiation to last visit on ADA therapy was 11 months (95% CI 4–25). The proportion of patients remaining on ADA therapy at 6 and 12 months after initiation was 70% and 56%, respectively. In the subset of patients who were biologic-naive at ADA initiation, the median time from ADA initiation to last visit on ADA therapy was 13 months (95% CI 6–29), with 78% and 62% remaining on ADA at 6 and 12 months, respectively (data not shown).

The probability of patients within the analysis remaining on ADA over time is presented as a time to discontinuation from ADA in Figure 1. The 3 most commonly reported reasons for discontinuing ADA treatment among the overall population included failure to maintain initial response (27%), inadequate initial response (16%), and minor side effect (14%); serious side effects accounted for 6% of reported reasons for discontinuation (data not shown). Similar frequencies of reasons for discontinuation were observed among the biologic-naive population.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Probability of continuing adalimumab treatment.

Incidence of events during ADA exposure

The IR per 100 PY of ADA exposure was 1.86 (95% CI 1.50–2.31) for serious infections, 0.15 (0.07–0.31) for CHF requiring hospitalization, 0.64 (0.50–0.84) for malignancy (excluding nonmelanoma skin cancers), and 0.33 (0.24–0.48) for all-cause mortality (Table 2). No cases of TB were reported during followup. The IR per 100 PY of ADA exposure for AE included in this study (excluding malignancy and mortality) leading to ADA discontinuation was 0.73 (0.52–1.03).

View this table:
  • View inline
  • View popup
Table 2.

Incidence of AEa among ADA initiators.

The incidence of events by duration of ADA exposure categories (≤ 1 yr, > 1 to 3 yrs, > 3 to 5 yrs, > 5 yrs) is presented in Figure 2. The incidence of serious infections was higher in the first year of therapy (3.44 per 100 PY, 95% CI 2.45–4.84) than in subsequent years, while other AE did not substantially vary by duration of exposure.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Incidence of events by duration of adalimumab exposure. Error bars indicate 95% CI. Serious infections included those that led to hospitalization or IV antibiotics. Malignancy excluded nonmelanoma skin cancer. CHF: congestive heart failure; IV: intravenous.

Time to first occurrence of AE of interest

Median times to first serious infection and malignancy among those experiencing each respective event were 12 months (95% CI 7–26) and 34 months (16–56), respectively. The proportion of patients not having a first occurrence of serious infection and malignancy at 6 months was 98.4% and 99.7%, respectively. This remained largely unchanged at 12 months, at which 97.5% and 99.4% of patients had not had an occurrence of serious infection or malignancy, respectively. Throughout the remainder of the evaluation period, the large majority of patients did not have an occurrence of serious infection or malignancy at 24, 36, 48, 60, 72 or 84 months (Supplementary Table 2, available with the online version of this article). Kaplan-Meier curves for the probability of not having a serious infection or having a malignancy event are presented in Figure 3 and Figure 4, respectively.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Probability of not having a serious infection.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Probability of not having a malignancy event.

SMR data

The age-adjusted and sex-adjusted SMR comparing the observed and expected number of deaths was 0.50 ± 0.32. The SMR reveals that there were an expected 62 mortalities within the ADA-initiating population, compared to only 31 deaths observed (data not shown).

DISCUSSION

With an increasing number of physicians prescribing disease-modifying antirheumatic medications for longterm chronic use, knowledge of the longterm safety profiles of such medications is critical in guiding providers in prescribing strategies that minimize the risk of serious AE for their patients. This retrospective analysis of a real-world US database of patients with RA treated with ADA immunotherapy is consistent with the safety profile previously established through RCT, open-label extension studies, and European RA registries.

An update of global longterm clinical trial safety data in adult patients treated with ADA for multiple indications (predominately RA studies), which included 29,987 patients with 56,951 PY of exposure, identified serious infections as the most frequent AE, with an IR of 4.6 events per 100 PY18. Our study found a lower IR per 100 PY for serious infections, which was higher during the first year of exposure (3.44, 95% CI 2.45–4.84) than in subsequent years. Previous studies have also shown the risk of infection to be higher earlier in treatment compared with later in treatment31. It may be the case that these AE were more strictly reported in the clinical trials, as compared with the Corrona registry, although given the serious nature of these AE, this seems unlikely. Patients in Corrona may have lower levels of disease activity compared to patients in the RCT. Previous studies have shown that increased RA disease activity is associated with an increased risk for serious infections24,32,33. Differences in the methodology used for the calculation of AE IR may also help explain the differences in the observed rates. Compared to the present study, which collected AE at the patient level, the global longterm clinical trials study collected AE at the event level, with multiple AE of the same type within an individual reflected in the IR. The global clinical trial analysis reported a lower number of deaths in patients with RA treated with ADA (SMR of 0.74) than would be expected in an age- and sex- adjusted population18, a number directionally similar to the SMR observed in our real-world analysis. For both analyses, underlying explanations for this result are not immediately clear.

Comparison of the Corrona registry findings with those from other real-world databases also reveals variations in outcomes across these analyses. The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) reported that no TNFi was associated with a statistically higher risk of serious infection than any other TNFi among a total of 19,282 patients contributing 46,771 PY of followup. BSRBR-RA reported an IR for serious infection of 5.42 per 100 PY among 7818 patients initiating ADA, which was higher than the first-year IR of serious infection reported for ADA-exposed patients in our study (IR 3.44)22. The IR for malignancy during a median followup of 3.5 years per patient in a BSRBR-RA cohort exposed to TNFi was more similar, although still slightly higher, than that observed in the present study (0.77 vs 0.64, respectively)21. During a total of 3 years of followup, the Anti-Rheumatic Therapy in Sweden biologics register reported an IR for mortality of 1.4 per 100 PY after exposure to ADA. In both studies, the IR observed may be higher than that reported in our analysis because of differences in median followup time20. Additionally, patients in Europe often have more restricted access to biologics and thus have higher levels of disease activity, greater use of prednisone, and higher levels of disability prior to biologic initiation, all of which influence the risk of infection24,34. Prevalence of clinical characteristics (e.g., smoking) and comorbidities (e.g., obesity) also varies between US and European registries, and may reflect the way comorbidity data were recorded as well as general cultural differences between countries. Differences in comorbidity profiles could create differences in the IR of AE23,24.

Comparing safety outcomes for ADA in US clinical practice using data from a large, nationwide cohort of patients with RA is a vital strength of our study. Owing to payer and regulatory differences, patient characteristics and access to biologic drugs can vary substantially between countries. Therefore, it is essential to obtain representative clinical evidence directly relevant to practicing rheumatologists in the US. A previous study showed that Medicare beneficiaries who were enrolled in Corrona share similar demographic and clinical characteristics with Medicare beneficiaries with claims for RA or visits to a rheumatology specialist who were not enrolled, thus suggesting that the results presented here may be generalizable to the broader RA population in the US35. The relative similarity of the AE findings of our analysis compared with prior clinical trials and other observational registry studies is reassuring, yet also highlights the importance of continuing to assess these outcomes over longer periods of time, and in more diverse populations.

Our study also has several limitations. First, ADA exposure time was limited for some patients. In total, 50% of patients used ADA for 1 year or less and only 16% of patients were exposed for 3 years or more. While serious infection event rates tend to be highest during the first 6–12 months of TNFi exposure36,37, the limited number of patients in our study with longer-term ADA exposure may not have allowed us to fully characterize the rates of serious infection as well as other AE such as malignancies because of the relative infrequency and longer-term onset of these AE. There is an inability to determine with certainty whether ADA exposure had an effect on the development of the AE measured, particularly those AE occurring after drug discontinuation, or conditions that typically take many years to develop (e.g., malignancy). We did not account for subsequent therapies initiated after ADA discontinuation and their potential effect on the occurrence of AE observed in our study. The SMR among this population was low, which could have caused undercounting of events within the Corrona registry. However, serious events are less likely to be underreported, and a low SMR was also found in the ESPRIT study, which evaluated the longterm safety and effectiveness of ADA in the treatment of psoriasis, and in studies evaluating the longterm safety of ADA across multiple indications15,17,18. Finally, the precision with which ADA discontinuation is measured in the Corrona registry may have resulted in misclassified exposure time. The date of discontinuation was recorded at the time of physician visit; however, there may be challenges with recall bias if the discontinuation is not well documented in the physician’s clinical notes.

This analysis of targeted data from the prospective Corrona real-world RA registry demonstrated ADA to have a safety profile consistent with previous studies and did not identify any new safety concerns with longterm ADA treatment. Therefore, with the addition of these real-world data in a large sample of US patients with RA, the previously understood benefit-risk profile of ADA for the treatment of RA remains unchanged. This confirmation of existing knowledge may reassure providers who are initiating and monitoring ADA in their patients.

Acknowledgment

Medical writing support was provided by Brandy Menges of JK Associates Inc., and editorial support was provided by Sebastian Reynolds and Fiona Woodward of JK Associates Inc. This support was funded by AbbVie.

Footnotes

  • Full Release Article. For details see Reprints and Permissions at jrheum.org.

  • Financial support for the study was provided by AbbVie, which manufactures adalimumab. AbbVie participated in the interpretation of data, and review and approval of the manuscript. The study was sponsored by Corrona LLC. Corrona LLC has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Crescendo, Eli Lilly and Co., Genentech, Gilead, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Roche, Merck, UCB, and Valeant. The study design and conduct were a collaboration between Corrona and AbbVie. L.R. Harrold is an employee and shareholder of Corrona LLC. C.J. Barr is an employee and shareholder of Corrona LLC. H.J. Litman is an employee of Corrona LLC. J. Griffith, S.S. Islam, D. Guo, J. Fay, and P. Zueger are employees of AbbVie Inc. and own AbbVie stock. J.D. Greenberg is an employee and shareholder of Corrona LLC. L.R. Harrold, MD, MPH, University of Massachusetts Medical School, and Corrona LLC; J. Griffith, PharmD, AbbVie; P. Zueger, PharmD, PhD, AbbVie; H.J. Litman, PhD, Corrona LLC; B. Gershenson, MPH, University of Massachusetts Medical School; S.S. Islam, MD, MSPH, DrPH, AbbVie; C.J. Barr, MPH, Corrona LLC; D. Guo, MD, PhD, AbbVie; J. Fay, MD, AbbVie; J.D. Greenberg, MD, MPH, Corrona LLC, and New York University School of Medicine.

  • Accepted for publication July 29, 2019.

Free online via JRheum Full Release option

REFERENCES

  1. 1.↵
    1. Kvien TK
    . Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):1–12.
    OpenUrlPubMed
  2. 2.↵
    1. Scott DL,
    2. Wolfe F,
    3. Huizinga TW
    . Rheumatoid arthritis. Lancet 2010;3769746:1094–108.
    OpenUrl
  3. 3.↵
    1. Avina-Zubieta JA,
    2. Choi HK,
    3. Sadatsafavi M,
    4. Etminan M,
    5. Esdaile JM,
    6. Lacaille D
    . Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Doran MF,
    2. Crowson CS,
    3. Pond GR,
    4. O’Fallon WM,
    5. Gabriel SE
    . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Naz SM,
    2. Symmons DP
    . Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:871–83.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Sator P
    . Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9:147–58.
    OpenUrl
  7. 7.↵
    1. Nam JL,
    2. Ramiro S,
    3. Gaujoux-Viala C,
    4. Takase K,
    5. Leon-Garcia M,
    6. Emery P,
    7. et al.
    Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516–28.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Barnabe C,
    2. Martin BJ,
    3. Ghali WA
    . Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522–9.
    OpenUrlCrossRef
  9. 9.↵
    1. Solomon DH,
    2. Reed GW,
    3. Kremer JM,
    4. Curtis JR,
    5. Farkouh ME,
    6. Harrold LR,
    7. et al.
    Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449–55.
    OpenUrl
  10. 10.↵
    1. Hochberg MC,
    2. Lebwohl MG,
    3. Plevy SE,
    4. Hobbs KF,
    5. Yocum DE
    . The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819–36.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Baecklun E,
    2. Iliadou A,
    3. Askling J,
    4. Ekbom A,
    5. Backlin C,
    6. Granath F,
    7. et al.
    Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692–701.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Dommasch ED,
    2. Abuabara K,
    3. Shin DB,
    4. Nguyen J,
    5. Troxel AB,
    6. Gelfand JM
    . The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized control trials. J Am Acad Dermatol 2011;64:1035–50.
    OpenUrlCrossRefPubMed
  13. 13.
    1. Keystone EC
    . Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of longterm data. J Rheumatol 2011;38:1552–62.
    OpenUrlAbstract/FREE Full Text
  14. 14.
    1. Greenberg JD,
    2. Reed G,
    3. Kremer JM,
    4. Tindall E,
    5. Kavanaugh A,
    6. Zheng C,
    7. et al.
    Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380–6.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Menter A,
    2. Thaci D,
    3. Wu JJ,
    4. Abramovits W,
    5. Kerdel F,
    6. Arikan D,
    7. et al.
    Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther 2017;7:365–81.
    OpenUrl
  16. 16.
    1. Buchbinder R,
    2. Van Doornum S,
    3. Staples M,
    4. Lassere M,
    5. March L
    . Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Musculoskelet Disord 2015;16:309.
    OpenUrl
  17. 17.↵
    1. Burmester GR,
    2. Panaccione R,
    3. Gordon KB,
    4. McIlraith MJ,
    5. Lacerda AP
    . Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013;72:517–24.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Burmester GR,
    2. Panaccione R,
    3. Gordon KB,
    4. Rosenbaum JT,
    5. Arikan D,
    6. Lau WL,
    7. et al.
    Long-term safety of adalimumab (HUMIRA) in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years [abstract]. Arthritis Rheumatol 2017;69 Suppl 10:2481.
    OpenUrl
  19. 19.↵
    1. Tracey D,
    2. Klareskog L,
    3. Sasso EH,
    4. Salfeld JG,
    5. Tak PP
    . Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Simard JF,
    2. Neovius M,
    3. Askling J;
    4. the ARTIS Study Group
    . Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Arthritis Rheum 2012;64:3502–10.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Mercer LK,
    2. Lunt M,
    3. Low AL,
    4. Dixon WG,
    5. Watson KD,
    6. Symmons DP,
    7. et al.
    Risk of solid cancer in patients exposed to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;74:1087–93.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Rutherford AI,
    2. Subesinghe S,
    3. Hyrich KL,
    4. Galloway JB
    . Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018;77:905–10.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Verstappen SM,
    2. Askling J,
    3. Berglind N,
    4. Franzen S,
    5. Frisell T,
    6. Garwood C,
    7. et al.
    Methodological challenges when comparing demographic and clinical characteristics of international observational registries. Arthritis Care Res 2015;67:1637–45.
    OpenUrlCrossRef
  24. 24.↵
    1. Curtis JR,
    2. Jain A,
    3. Askling J,
    4. Bridges SL Jr,
    5. Carmona L,
    6. Dixon W,
    7. et al.
    A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2–14e11.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Kottak N,
    2. Tesser J,
    3. Leibowitz E,
    4. Rosenberg M,
    5. Parenti D,
    6. DeHoratius R
    . Ethnographic observational study of the biologic initiation conversation between rheumatologists and biologic-naive rheumatoid arthritis patients. Arthritis Care Res 2018;70:997–1004.
    OpenUrl
  26. 26.↵
    1. Kremer JM
    . The CORRONA database. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S172–7.
    OpenUrlPubMed
  27. 27.↵
    1. Fisher MC,
    2. Furer V,
    3. Hochberg MC,
    4. Greenberg JD,
    5. Kremer JM,
    6. Curtis JR,
    7. et al.
    Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord 2012;13:85.
    OpenUrlPubMed
  28. 28.↵
    1. Solomon DH,
    2. Kremer J,
    3. Curtis JR,
    4. Hochberg MC,
    5. Reed G,
    6. Tsao P,
    7. et al.
    Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920–5.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Curtis JR,
    2. Patkar NM,
    3. Jain A,
    4. Greenberg J,
    5. Solomon DH
    . Validity of physician-reported hospitalized infections in a US arthritis registry. Rheumatology 2009;48:1269–72.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Murphy SL,
    2. Xu J,
    3. Kochanek KD,
    4. Curtin SC,
    5. Arias E
    . Deaths: final data for 2015. Natl Vital Stat Rep 2017;66:1–75.
    OpenUrlPubMed
  31. 31.↵
    1. Dixon WG,
    2. Symmons DP,
    3. Lunt M,
    4. Watson KD,
    5. Hyrich KL;
    6. British Society for Rheumatology Biologics Register Control Centre Consortium,
    7. et al.
    Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896–904.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Emery P,
    2. Gallo G,
    3. Boyd H,
    4. Morgan CL,
    5. Currie CJ,
    6. Poole CD,
    7. et al.
    Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2014;32:653–60.
    OpenUrl
  33. 33.↵
    1. Weaver A,
    2. Troum O,
    3. Hooper M,
    4. Koenig AS,
    5. Chaudhari S,
    6. Feng J,
    7. et al.
    Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 2013;40:1275–81.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. National Institute for Health and Care Excellence
    . Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375). [Internet. Accessed November 29, 2019.] Available from: www.nice.org.uk/guidance/ta375
  35. 35.↵
    1. Curtis JR,
    2. Chen L,
    3. Bharat A,
    4. Delzell E,
    5. Greenberg JD,
    6. Harrold L,
    7. et al.
    Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res 2014;66:1790–8.
    OpenUrl
  36. 36.↵
    1. Galloway JB,
    2. Hyrich KL,
    3. Mercer LK,
    4. Dixon WG,
    5. Fu B,
    6. Ustianowski AP,
    7. et al.
    Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124–31.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Cobo-Ibanez T,
    2. Descalzo MA,
    3. Loza-Santamaria E,
    4. Carmona L,
    5. Muñoz-Fernández S
    . Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int 2014;34:953–61.
    OpenUrl

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 7
1 Jul 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry
Leslie R. Harrold, Jenny Griffith, Patrick Zueger, Heather J. Litman, Bernice Gershenson, Syed S. Islam, Christine J. Barr, Dianlin Guo, Jonathan Fay, Jeffrey D. Greenberg
The Journal of Rheumatology Jul 2020, 47 (7) 959-967; DOI: 10.3899/jrheum.190260

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry
Leslie R. Harrold, Jenny Griffith, Patrick Zueger, Heather J. Litman, Bernice Gershenson, Syed S. Islam, Christine J. Barr, Dianlin Guo, Jonathan Fay, Jeffrey D. Greenberg
The Journal of Rheumatology Jul 2020, 47 (7) 959-967; DOI: 10.3899/jrheum.190260
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
    • ONLINE SUPPLEMENT
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

RHEUMATOID ARTHRITIS
DRUG SAFETY
ADALIMUMAB
ADVERSE EFFECTS
REGISTRIES

Related Articles

Cited By...

More in this TOC Section

  • Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis
  • Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months
  • Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis
Show more Rheumatoid Arthritis

Similar Articles

Keywords

  • rheumatoid arthritis
  • drug safety
  • ADALIMUMAB
  • adverse effects
  • registries

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire